Corporate Profile

Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and preclinical development of novel small-molecule therapeutics for neurological diseases. Alectos focuses on identifying and developing innovative disease-modifying strategies to address complex neurological conditions for which there are no effective treatments, including Alzheimer’s disease and Parkinson’s disease.

The Alectos pipeline is directed towards the development of new agents to treat patients living with neurological disorders. Our glucocerebrosidase 2 (GBA2) program represents a disease-modifying strategy to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease and Niemann Pick type C disease. This program has recently been partnered with Biogen. Our O-GlcNAcase (OGA) program focuses on the development of therapies to prevent the accumulation and spread of toxic protein aggregates in the brain. Alectos partnered with Merck to pioneer the development of the first OGA inhibitor to enter clinical studies. This program has now returned to Alectos, and we are applying our broad intellectual property and deep knowledge in this space to advance our novel OGA inhibitors as disease-modifying treatments for neurodegenerative diseases including Alzheimer’s disease, frontotemporal dementia, and ischemic stroke. We welcome partnership inquiries regarding our OGA inhibitor program.

Alectos Therapeutics

Meet Our Team

Ernest McEachern, PhD
David Vocadlo, PhD
Yuanxi Zhou, PhD
Director of Medicinal Chemistry
Renee Mosi, PhD
Project Manager

Scientific Advisory Board

Gary J. Bridger, PhD
Gideon J. Davies, PhD
Cheng-Xin Gong, MD
Robert N. Young, PhD